Consistency of response

Achieve a consistent platelet response
with Doptelet¹

In a Phase III, multicentre, randomised, double-blind, parallel-group, placebo-controlled study, adult patients with chronic ITP were randomised 2:1 to Doptelet 5–40 mg once a day (n=32) or placebo (n=17). Doptelet was initiated at 20 mg once a day, and dose was titrated from days 5±1 to 28. Treatment continued until week 26, at which point eligible patients enrolled into an open-label extension phase.¹

Primary endpoint: Doptelet patients (n=32) achieved a median of 12.4 weeks at or above the platelet target (≥50 × 109/L) without rescue therapy vs 0.0 weeks with placebo (p<0.0001).¹

Secondary endpoint: The median platelet count was consistently higher with Doptelet vs placebo from day 8 (80.5 x 10⁹/L vs 8 x 10⁹/L).¹

Median platelet count over time¹

Consistent efficacy regardless of prior TPO-RA treatment experience²

In a post-hoc subgroup analysis of the Phase III study, treatment with Doptelet was equally effective among patients with and without prior TPO-RA experience.²

Challenge your expectations by starting with or switching to Doptelet

Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).³

ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.

References

1. Jurczak W et al. Br J Haematol. 2018; 183(3):479–490. 2. McCrae KR et al. ISTH. 2019. 3. Doptelet EMC Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/11837/smpc#gref Last accessed: April 2025.

Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App
Store (for United Kingdom) and www.hpra.ie (for Republic of Ireland). Adverse events should also be reported to Swedish Orphan Biovitrum Ltd at [email protected] or Telephone +44 (0) 800 111 4754

PP-18707

Sep, 2025